Sequential chemotherapy: rationale and clinical trial design in advanced non-small-cell carcinoma.

Abstract:

:Recent developments in the chemotherapy of advanced and metastatic non small-cell lung cancer have led to significant, albeit modest, improvements in survival and quality of life. The plethora of new agents with activity in this disease has led to questions as to how these drugs can best be added to existing regimens. Traditionally, the paradigm of combination chemotherapy has dominated this approach with new agents added to older regimens. Unfortunately, this will frequently lead to additive toxicity and necessitate reduction in the doses of individual components of the combination. The planned sequential administration of new chemotherapy agents circumvents this problem. Additionally, considerable theoretical, biological, and clinical evidence supports this approach. This paper reviews the rationale for this strategy and discusses initial data from a pilot trial of this approach.

journal_name

Clin Lung Cancer

journal_title

Clinical lung cancer

authors

Edelman MJ,Gandara DR

doi

10.3816/clc.1999.n.009

keywords:

subject

Has Abstract

pub_date

1999-11-01 00:00:00

pages

122-7; discussion 128-9

issue

2

eissn

1525-7304

issn

1938-0690

pii

S1525-7304(11)70569-1

journal_volume

1

pub_type

杂志文章
  • Cancer treatment involving oncolytic viruses.

    abstract::Viruses capable of inducing lysis of malignant cells through their replication process are known as "oncolytic" viruses. Clinical trials in oncology have been performed with oncolytic viruses for nearly fifty years. Both systemic and intratumoral routes of administration have been explored. Toxicity has generally been...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.3816/clc.1999.n.003

    authors: Nemunaitis JJ

    更新日期:1999-08-01 00:00:00

  • Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.

    abstract:BACKGROUND:First-line treatment of non-small-cell lung cancer (NSCLC) has undergone a paradigm shift to platinum combination therapy together with an immune checkpoint inhibitor (ICI). Bevacizumab is expected to enhance not only chemotherapy but also the efficacy of ICIs through blockade of vascular endothelial growth ...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2020.03.010

    authors: Shiraishi Y,Kishimoto J,Tanaka K,Sugawara S,Daga H,Hirano K,Azuma K,Hataji O,Hayashi H,Tachihara M,Mitsudomi T,Seto T,Nakagawa K,Yamamoto N,Okamoto I

    更新日期:2020-09-01 00:00:00

  • Classifications of n2 non-small-cell lung cancer based on the number and rate of metastatic mediastinal lymph nodes.

    abstract:BACKGROUND:Subdivisions of N2 non-small-cell lung cancer (NSCLC) cases based on metastatic status of mediastinal and non-mediastinal lymph nodes have been proposed. This study aimed to evaluate N2 disease classification by mediastinal lymph nodes alone. PATIENTS AND METHODS:We reviewed 187 patients with NSCLC pN1-N2 w...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2013.04.012

    authors: Ito M,Yamashita Y,Tsutani Y,Misumi K,Harada H,Miyata Y,Okada M

    更新日期:2013-11-01 00:00:00

  • The emerging role of biomarkers in advanced non-small-cell lung cancer.

    abstract::Novel therapies, particularly those that target vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR), have improved the treatment of advanced non-small-cell lung cancer (NSCLC). The search continues for biomarkers that can predict which patients are most likely to benefit from these th...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CLC.2010.n.019

    authors: Socinski MA

    更新日期:2010-05-01 00:00:00

  • Effect of Thoracic Radiotherapy Timing and Fractionation on Survival in Nonmetastatic Small Cell Lung Carcinoma.

    abstract:BACKGROUND:The optimal timing of thoracic radiation therapy (RT) in relation to chemotherapy is unknown in the treatment of nonmetastatic small cell lung cancer (SCLC). We analyzed the National Cancer Data Base (NCDB) to assess the effect on overall survival (OS) of RT timing with chemotherapy for patients with SCLC. ...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2016.07.009

    authors: Wong AT,Rineer J,Schwartz D,Becker D,Safdieh J,Osborn V,Schreiber D

    更新日期:2017-03-01 00:00:00

  • Intercalated Chemotherapy and Epidermal Growth Factor Receptor Inhibitors for Patients With Advanced Non-Small-cell Lung Cancer: A Systematic Review and Meta-analysis.

    abstract::Randomized clinical trials (RCTs) of concurrent epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) plus chemotherapy for unselected patients with advanced non-small-cell lung cancer (NSCLC) produced negative results. Intercalated administration could avoid the reduction of chemotherapy activity du...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.cllc.2016.08.006

    authors: La Salvia A,Rossi A,Galetta D,Gobbini E,De Luca E,Novello S,Di Maio M

    更新日期:2017-01-01 00:00:00

  • Assessment of Selection Criteria for Low-Dose Lung Screening CT Among Asian Ethnic Groups in Taiwan: From Mass Screening to Specific Risk-Based Screening for Non-Smoker Lung Cancer.

    abstract:BACKGROUND:The National Lung Screening Trial (NLST) showed low-dose screening chest computed tomography (CT) reduced the lung cancer mortality rate up to 20% in high-risk patients in the United States. We aimed to investigate the impact of applying the NLST eligibility criteria to the population in Taiwan, and to ident...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2016.03.004

    authors: Wu FZ,Huang YL,Wu CC,Tang EK,Chen CS,Mar GY,Yen Y,Wu MT

    更新日期:2016-09-01 00:00:00

  • Prevalence and clinical significance of incidental and clinically suspected venous thromboembolism in lung cancer patients.

    abstract:BACKGROUND:It is unclear what proportion of VTE events in lung cancer patients are incidentally discovered and whether incidental events affect mortality. PATIENTS AND METHODS:We conducted a retrospective cohort study of lung cancer patients seen at the University of Rochester between January 1, 2006 and December 31, ...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2013.06.003

    authors: Connolly GC,Menapace L,Safadjou S,Francis CW,Khorana AA

    更新日期:2013-11-01 00:00:00

  • Three-dimensional conformal radiation therapy (3D-CRT) for early-stage non-small-cell lung cancer.

    abstract::The standard treatment for early-stage non-small-cell lung cancer is surgical resection. However, many patients are inoperable due to medical comorbidities. Thirty-two medically inoperable patients with early-stage non-small-cell lung cancer were treated with 3-dimensional conformal radiation therapy between January 1...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.3816/clc.2001.n.025

    authors: Rosenzweig KE,Dladla N,Schindelheim R,Sim SE,Braban LE,Venkataraman ES,Leibel SA

    更新日期:2001-11-01 00:00:00

  • Genomic and proteomic analyses of vascular endothelial growth factor and insulin-like growth factor-binding protein 3 in lung adenocarcinomas.

    abstract::Vascular endothelial growth factor (VEGF) is regulated by the hypoxia-inducible factor 1 (HIF1) pathway and is implicated in tumor progression and patient survival in many types of cancer. Insulin-like growth factor-binding protein 3 (IGFBP3) is also regulated by HIF1 but works in a completely different manner by modu...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.3816/CLC.2004.n.011

    authors: Gharib TG,Chen G,Huang CC,Misek DE,Iannettoni MD,Hanash SM,Orringer MB,Beer DG

    更新日期:2004-03-01 00:00:00

  • Toxicity and Pharmacokinetic Studies of Aerosolized Clinical Grade Azacitidine.

    abstract:BACKGROUND:Azacitidine as an effective epigenetic therapeutic agent has not been used as an aerosol form to treat lung cancer patients. We aerosolized clinical grade azacitidine (Aza), optimized the formulation, and studied its pharmacokinetics and toxicity in mice. METHODS:Extrusion-precipitation method and DNA methy...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2015.09.005

    authors: Qiu X,Liang Y,Sellers RS,Perez-Soler R,Zou Y

    更新日期:2016-05-01 00:00:00

  • Second Primary Non-Small-Cell Lung Cancer After Head and Neck Cancer: A Population-Based Study of Clinical and Pathologic Characteristics and Survival Outcomes in 3597 Patients.

    abstract:INTRODUCTION:Retrospective studies have shown an increased risk of second primary lung cancer in patients with a history of head and neck cancer (HNC). No population-based study has examined the overall survival (OS) outcomes of patients with second primary non-small-cell lung cancer (NSCLC) after HNC comparison with p...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2019.02.017

    authors: Budnik J,DeNunzio NJ,Singh DP,Milano MT

    更新日期:2020-05-01 00:00:00

  • Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.

    abstract:BACKGROUND:In lung adenocarcinoma, inactivation of the tumor suppressor p53 may abrogate a safeguard mechanism preventing the development of tumors with activating mutations in EGFR or KRAS. To assess this hypothesis, we analyzed TP53 mutations and downregulation of p14(arf), a negative regulator of p53 activated by on...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2013.08.003

    authors: Cortot AB,Younes M,Martel-Planche G,Guibert B,Isaac S,Souquet PJ,Commo F,Girard P,Fouret P,Brambilla E,Hainaut P,Soria JC

    更新日期:2014-03-01 00:00:00

  • The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review.

    abstract::The ability to reliably distinguish synchronous primary non-small-cell lung cancer (NSCLC) from intrapulmonary metastatic spread affects staging and treatment decisions in resected NSCLC. Adjuvant therapy for early-stage NSCLC is complicated and recommendations are primarily based on older data from trials that used n...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.cllc.2015.03.004

    authors: Klempner SJ,Ou SH,Costa DB,VanderLaan PA,Sanford EM,Schrock A,Gay L,Ali SM,Miller VA

    更新日期:2015-09-01 00:00:00

  • ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer.

    abstract:BACKGROUND:ROS1 gene fusions cause several cancers by constitutively activating the ROS1 tyrosine kinase receptor. ROS1-targeted inhibitor therapy improves survival in the approximately 1% to 2% of patients with lung adenocarcinoma with ROS1 gene fusions. Although fluorescence in situ hybridization (FISH) is the standa...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2014.10.003

    authors: Boyle TA,Masago K,Ellison KE,Yatabe Y,Hirsch FR

    更新日期:2015-03-01 00:00:00

  • Location Matters: Stage I Non-Small-cell Carcinomas of the Lower Lobes Treated With Stereotactic Body Radiation Therapy Are Associated With Poor Outcomes.

    abstract:INTRODUCTION:The lung is a heterogeneous organ with relative overperfusion of the lung bases. We determined whether a lower lobe primary tumor location was associated with poor outcomes in the setting of stage I non-small-cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT). PATIENTS AND ME...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2016.09.001

    authors: Shaverdian N,Veruttipong D,Wang J,Kupelian P,Steinberg M,Lee P

    更新日期:2017-03-01 00:00:00

  • Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Non-Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab.

    abstract:BACKGROUND:Cancer-associated macrophage-like cells (CAMLs) are a potential peripheral blood biomarker for disease progression. This study used data from a phase 2 clinical trial to evaluate prognostic utility of CAMLs for locally advanced non-small-cell lung cancer treated with definitive chemoradiotherapy (CRT) and at...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2020.06.016

    authors: Augustyn A,Adams DL,He J,Qiao Y,Verma V,Liao Z,Tang CM,Heymach JV,Tsao AS,Lin SH

    更新日期:2020-06-20 00:00:00

  • The Effect of Primary Care Physician Knowledge of Lung Cancer Screening Guidelines on Perceptions and Utilization of Low-Dose Computed Tomography.

    abstract:INTRODUCTION:Lung cancer screening (LCS) with low-dose computed tomography (LDCT) is recommended by the U.S. Preventive Services Task Force (USPSTF) in high-risk patients, but a minority of eligible people are screened. It is not clear whether knowledge of USPSTF recommendations among primary care physicians (PCP) affe...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2017.05.013

    authors: Raz DJ,Wu GX,Consunji M,Nelson RA,Kim H,Sun CL,Sun V,Kim JY

    更新日期:2018-01-01 00:00:00

  • Quality of life and the treatment of advanced lung cancer.

    abstract::Lung cancer is the leading cause of cancer deaths worldwide, with the majority of patients presenting with advanced disease. Despite the introduction of newer therapeutic agents and modest survival improvement, the overall prognosis for these patients is poor. The goals of therapy should therefore include improvement ...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CLC.2003.n.018

    authors: Plunkett TA,Chrystal KF,Harper PG

    更新日期:2003-07-01 00:00:00

  • Immune modulation as a therapeutic strategy for non-small-cell lung cancer.

    abstract::Active tumor immunotherapy may provide hope for patients with non-small-cell lung cancer (NSCLC) because, in more than 20 years, current therapies have yet to change mortality statistics. Creating an efficacious vaccine involves selection of important tumor antigens and formulation of their immunogenic epitopes into a...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章,评审

    doi:10.3816/clc.2008.s.003

    authors: Holt GE,Disis ML

    更新日期:2008-02-01 00:00:00

  • EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review.

    abstract::Expert consensus guidelines have defined minimum requirements for routine testing and identification of classical epidermal growth factor (EGFR) mutations (ie, exon 19 deletions and exon 21 L858R substitution) and anaplastic lymphoma kinase (ALK) rearrangements in advanced non-small-cell lung cancers of adenocarcinoma...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.cllc.2016.05.016

    authors: Sheikine Y,Rangachari D,McDonald DC,Huberman MS,Folch ES,VanderLaan PA,Costa DB

    更新日期:2016-11-01 00:00:00

  • Pulmonary function tests as a predictor of quantitative and qualitative outcomes after thoracic surgery for lung cancer.

    abstract:BACKGROUND:Pulmonary function tests are used to select patients with non-small-cell lung cancer (NSCLC) suitable for thoracic surgery. We studied the impact of pulmonary function tests on both quantitative (morbidity, mortality, and overall survival [OS]) and qualitative (quality of life [QOL]) outcomes of patients und...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.3816/CLC.2007.n.042

    authors: Greillier L,Thomas P,Loundou A,Doddoli C,Badier M,Auquier P,Barlési F

    更新日期:2007-11-01 00:00:00

  • Chemotherapy and Radiation Versus Chemotherapy Alone for Elderly Patients With N3 Stage IIIB NSCLC.

    abstract:BACKGROUND:Standard treatment for stage III non-small-cell lung cancer (NSCLC) is concurrent chemotherapy and radiation (chemo-RT). However, N3 stage IIIB disease portends a worse prognosis and the tolerability of chemo-RT in patients ≥70 years old is a concern. In this analysis, we evaluate the survival of patients wi...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2019.04.003

    authors: Qin A,Lusk E,Daignault-Newton S,Schneider BJ

    更新日期:2019-07-01 00:00:00

  • Costs and ethical issues related to first-line treatment of metastatic non-small-cell lung cancer: considerations from a public healthcare system perspective.

    abstract::Metastatic non-small-cell lung cancer is generally not considered to be curable, and the overall 5-year survival rate is less than 1%. Despite this poor prognosis, palliative chemotherapy can increase time and quality of life in the advanced-disease setting. New chemotherapy treatments and targeted therapies are avail...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2011.06.007

    authors: Bosch-Barrera J,Quer N,Brunet J

    更新日期:2011-11-01 00:00:00

  • Patients with lung cancer with metachronous or synchronous gastric cancer.

    abstract:BACKGROUND:There are few reports of treatment and outcome for patients with metachronous or synchronous lung and gastric cancers. To evaluate them, we conducted a retrospective study. PATIENTS AND METHODS:The medical records of patients with lung cancer who previously or simultaneously had gastric cancer seen in our d...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.3816/CLC.2009.n.079

    authors: Kurishima K,Satoh H,Kagohashi K,Homma S,Nakayama H,Ohara G,Ishikawa H,Hizawa N

    更新日期:2009-11-01 00:00:00

  • Comparing Outcomes of Patients With Early-Stage Non-Small-Cell Lung Cancer Treated With Stereotactic Body Radiotherapy Based on Frailty Status.

    abstract:INTRODUCTION:Frailty of surgical patients has been associated with worse outcomes. There is limited literature discussing frailty in patients with lung cancer treated with stereotactic body radiotherapy (SBRT). This study assesses the relationship between frailty and overall survival (OS), tumor control, and toxicity i...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2018.05.008

    authors: Raghavan G,Shaverdian N,Chan S,Chu FI,Lee P

    更新日期:2018-09-01 00:00:00

  • PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III no

    abstract::This clinical trial summary provides the background and rationale for a randomized trial examining the benefits of pemetrexed/ cisplatin chemotherapy combined with radiation followed by consolidation pemetrexed in patients with unresectable stage IIIA/B non-small-cell lung cancer. The rationale for the selection of th...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章,随机对照试验

    doi:10.3816/CLC.2009.n.027

    authors: Vokes EE,Senan S,Treat JA,Iscoe NA

    更新日期:2009-05-01 00:00:00

  • Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.

    abstract:INTRODUCTION:Real-world data on current treatment practices for non-small-cell lung cancer (NSCLC) are needed to understand the place in therapy and potential economic impact of newer therapies. PATIENTS AND METHODS:This retrospective cohort study identified patients ≥ 65 years old in the Surveillance, Epidemiology, a...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2018.05.016

    authors: Arunachalam A,Li H,Bittoni MA,Camacho R,Cao X,Zhong Y,Lubiniecki GM,Carbone DP

    更新日期:2018-09-01 00:00:00

  • Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity.

    abstract::Epidermal growth factor receptor (EGFR) inhibitors are associated with unique and dramatic dermatologic side effects. Skin rash is the dose-limiting factor for all EGFR inhibitors and is usually dose related and reversible. Microbiologic stains and cultures from skin rash usually do not show an infectious cause. We re...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.3816/CLC.2008.n.010

    authors: Grenader T,Gipps M,Goldberg A

    更新日期:2008-01-01 00:00:00

  • Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.

    abstract:INTRODUCTION:Non-small-cell lung cancer (NSCLC) patients harboring ALK or ROS1 rearrangements invariably acquire resistance to the first- and second-generation tyrosine kinase inhibitors (TKIs), most notably ALK G1202R and ROS1 G2032R. Lorlatinib, a novel third-generation TKI, produced remarkable results from the first...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2018.12.020

    authors: Lee J,Sun JM,Lee SH,Ahn JS,Park K,Choi Y,Ahn MJ

    更新日期:2019-05-01 00:00:00